Missed Opportunities in Geriatric Oncology Research.
clinical trials
data analysis
data reporting
geriatric oncology
medical oncology
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
received:
13
02
2023
accepted:
15
02
2023
medline:
10
5
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
The field of geriatric oncology has made significant progress in recent decades, but there are still missed opportunities in important areas of research. One issue is the underrepresentation of older patients, especially those aged 75 years and older, in clinical trials. This has resulted in a lack of high-quality data for the care of this population, and the American Society of Clinical Oncology has called for an increase in the evidence base for older patients with cancer. The second missed opportunity is the chance to gather important knowledge from older patients participating in clinical trials, such as medications, social support, insurance, and financial information. These data can be easily collected and incorporated into the trial design to enhance the information available to researchers and clinicians. The third missed opportunity is the chance to robustly analyze and report clinical trial data for the benefit of geriatric oncology research. Many trials only report a median age and range, which is a disservice to both the participants and the patients who will be treated based on the study results. To advance geriatric oncology research, the necessary data need to be collected, analyzed, and reported through appropriate representation of older patients, collection of essential information, and thorough analysis and communication of results. Clinical trial design needs to include geriatric baseline parameters, and Cancer Therapy Evaluation Program (CTEP) has modified its template to include these parameters.
Identifiants
pubmed: 36940296
pii: 7081220
doi: 10.1093/oncolo/oyad072
pmc: PMC10166148
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-375Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
J Clin Oncol. 2013 Oct 10;31(29):3711-8
pubmed: 24019549
J Geriatr Oncol. 2020 Apr;11(3):369-379
pubmed: 31932259
J Clin Oncol. 2012 Mar 10;30(8):893-4
pubmed: 22331937
J Geriatr Oncol. 2016 Jul;7(4):293-304
pubmed: 27197916
J Geriatr Oncol. 2016 Jul;7(4):234-41
pubmed: 27197914
J Geriatr Oncol. 2020 Mar;11(2):327-334
pubmed: 31375399
CA Cancer J Clin. 2021 Jan;71(1):78-92
pubmed: 33002206
J Clin Oncol. 2017 Sep 1;35(25):2871-2874
pubmed: 28628364
J Clin Oncol. 2014 Aug 20;32(24):2587-94
pubmed: 25071116
Lancet. 2021 Nov 20;398(10314):1894-1904
pubmed: 34741815
J Clin Oncol. 2015 Nov 10;33(32):3826-33
pubmed: 26195697
Expert Opin Investig Drugs. 2017 Oct;26(10):1099-1102
pubmed: 28814118
N Engl J Med. 2021 Sep 16;385(12):1062-1065
pubmed: 34506087
J Clin Oncol. 2012 Jun 10;30(17):2036-8
pubmed: 22547597
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
J Geriatr Oncol. 2020 Mar;11(2):355-358
pubmed: 31326391